STOCK MARKET BSE NSE

Zydus Cadila gets USFDA nod for anesthesia drug

The medication is used as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Published: 05th May 2018 03:19 PM  |   Last Updated: 05th May 2018 03:19 PM   |  A+A-

Medicine

Image used for representational purpose only.

By PTI

NEW DELHI: Drug firm Zydus Cadila today said it has received an approval from the US health regulator to market Succinylcholine Chloride injection, used as part of general anesthesia procedure, in the American market.

The company has received an approval from the United States Food and Drug Administration (USFDA) to market its product in the US market, Zydus Cadila said in a statement.

The medication is used as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

The product would be manufactured at the group's Moraiya, Ahmedabad-based formulations manufacturing facility.

The company said it has also received tentative approval for Plerixafor injection, used in treating certain type of blood cancers.

Zydus group now has more than 190 approvals from the USFDA and has so far filed over 320 abbreviated new drug applications (ANDAs) since the commencement of the filing process in financial year 2003-04.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp